The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Open accessAbstract
We examined the effect of three months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo peripheral adipocyte insulin sensitivity as assessed by glycerol release in microdialysis from subcutaneous fat during a two-step (20 and 120 mU · m−2 · min−1) hyperinsulinemic-euglycemic clamp in nine type 2 diabetic subjects. In addition, the effects of rosiglitazone on liver and muscle triglyceride content were assessed by 1H-nuclear magnetic resonance spectroscopy. Rosiglitazone treatment resulted in a 68% (P < 0.002) and a 20% (P < 0.016) improvement in insulin-stimulated glucose metabolism during the low- and high- dosage−insulin clamps, respectively, which was associated with ∼40% reductions in plasma fatty acid concentration (P < 0.05) and hepatic triglyceride content (P < 0.05). These changes were associated with a 39% increase in extramyocellular lipid content (P < 0.05) and a 52% increase in the sensitivity of peripheral adipocytes to the inhibitory effects of insulin on lipolysis (P = 0.04). In conclusion, these results support the hypothesis that thiazolidinediones enhance insulin sensitivity in patients with type 2 diabetes by promoting increased insulin sensitivity in peripheral adipocytes, which results in lower plasma fatty acid concentrations and a redistribution of intracellular lipid from insulin responsive organs into peripheral adipocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies by our group (9, 17-20) and others (7, 21, 22) have demonstrated a strong relationship between triglyceride content in liver and muscle and insulin resistance in these tissues.”
From Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy (2002) · cites this paper as [9]
In the citing paper
“Treatment for 3 months with rosiglitazone was associated with an almost 40% reduction in hepatic triglyceride content, and roughly 40% increase in extramyocellular triglyceride concentration, and improved suppression of adipocyte lipolysis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Treatment for 3 months with rosiglitazone was associated with an almost 40% reduction in hepatic triglyceride content, and roughly 40% increase in extramyocellular triglyceride concentration, and improved suppression of adipocyte lipolysis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Though no reductions in the concentration of intramyocellular triglyceride were noted in this study, rosiglitazone improved insulin-mediated whole-body glucose disposal, consistent with improvements in muscle insulin sensitivity.”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Treatment for 3 months with rosiglitazone was associated with an almost 40% reduction in hepatic triglyceride content, and roughly 40% increase in extramyocellular triglyceride concentration, and improved suppression of adipocyte lipolysis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Thiazolidinediones, which are potent PPARγ agonists, can effectively reduce hepatic steatosis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Moreover, reductions in intracellular diacylglycerol content account for the improvements in insulin sensitivity after weight loss81 and therapy with thiazolidinediones.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Though no reductions in the concentration of intramyocellular triglyceride were noted in this study, rosiglitazone improved insulin-mediated whole-body glucose disposal, consistent with improvements in muscle insulin sensitivity.”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“The TZDs improve insulin resistance by increasing glucose disposal in muscle and decreasing hepatic glucose output.26”
From A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis (2004) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Self-citationDENSITOMETRIC ANALYSIS OF BODY COMPOSITION: REVISION OF SOME QUANTITATIVE ASSUMPTIONS*
Brožek, J., Grande, F., Anderson, J. T., & Keys, A. B. (1963) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1963.tb17079.x · Cited by 2,263
Mechanism of free fatty acid-induced insulin resistance in humans.
Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W., & Shulman, G. I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118742 · Cited by 1,539
Self-citationDresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Self-citationGriffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K., Barucci, N., Lee, D., Goodyear, L. J., Kraegen, E. W., White, M. F., & Shulman, G. I. (1999) · Diabetes · doi:10.2337/diabetes.48.6.1270 · Cited by 1,267
Self-citationKrssak, M., Falk Petersen, K., Dresner, A., DiPietro, L., Vogel, S. M., Rothman, D. L., Shulman, G. I., & Roden, M. (1999) · Diabetologia · doi:10.1007/s001250051123 · Cited by 1,264
Self-citation
Cited by
Sorted by citations
Items 301–400 of 643
Schrauwen‐Hinderling, V. B., Mensink, M., Hesselink, M. K. C., Sels, J.-P. J. E., Kooi, M. E., & Schrauwen, P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0267 · Cited by 42
Puttabyatappa, M., Andriessen, V., Mesquitta, M., Zeng, L., Pennathur, S., & Padmanabhan, V. (2017) · Endocrinology · doi:10.1210/en.2017-00460 · Cited by 42
Improved insulin sensitivity and islet function after PPARδ activation in diabetic db/db mice
Winzell, M. S., Wulff, E. M., Olsen, G. S., Sauerberg, P., Gotfredsen, C. F., & Åhrén, B. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.053 · Cited by 42
Markolf Hanefeld, E., Patwardhan, R., & Jones, N. P. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.12.003 · Cited by 42
Short-Term Curcumin Gavage Sensitizes Insulin Signaling in Dexamethasone-Treated C57BL/6 Mice
Tian, L., Zeng, K., Shao, W., Yang, B. B., Fantus, I. G., Weng, J., & Jin, T. (2015) · Journal of Nutrition · doi:10.3945/jn.115.216853 · Cited by 41
Liu, G., Grifman, M., Macdonald, J. E., Möller, P., Wong‐Staal, F., & Li, Q. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0200 · Cited by 41
Tsai, W., Chang, T.-H., Sun, W., Chan, H., Wu, C.-C., Hsu, P., Cheng, J., & Yu, M. (2017) · Oncotarget · doi:10.18632/oncotarget.20248 · Cited by 41
Jiang, Y., Wu, L., Zhu, X., Bian, H., Gao, X., & Xia, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02092-2 · Cited by 46
Kong, Z., Sudirman, S., Hsu, Y.-C., Su, C.-Y., & Kuo, H.-P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184485 · Cited by 42
Cellular mechanism of insulin resistance in skeletal muscle.
Petersen, K. F., & Shulman, G. I. (2002) · Europe PMC (PubMed Central) · Cited by 40
Self-citationFogari, R., Maffioli, P., Mugellini, A., Zoppi, A., Lazzari, P., & Derosa, G. (2011) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32834ba188 · Cited by 40
The patient with diabetes mellitus and heart failure: at-risk issues
Giles, T. D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.017 · Cited by 40
Combined Use of Rosiglitazone and Fenofibrate in Patients With Type 2 Diabetes
Boden, G. H., Homko, C. J., Mozzoli, M. A., Zhang, M., Kresge, K. M., & Cheung, P. (2006) · Diabetes · doi:10.2337/db06-0481 · Cited by 40
Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies
Heald, M., & Cawthorne, M. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_2 · Cited by 41
β‐Cell mass plasticity in type 2 diabetes
Prato, S. D., Wishner, W. J., Gromada, J., & Schluchter, B. J. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1462-8902.2004.00360.x · Cited by 39
Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD
Lin, S., Lin, Y., Kuo, S., Hsu, Y., & Hung, Y.-J. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00844-8 · Cited by 39
Arulmozhi, D. K., Dwyer, D. S., & Bodhankar, S. L. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.06.016 · Cited by 38
Wang, C., Leung, C.-H., Liu, S.-C., & Chung, C.-H. (2006) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60202-3 · Cited by 38
Rosiglitazone Prevents Free Fatty Acid-Induced Vascular Endothelial Dysfunction
Mittermayer, F., Schaller, G., Pleiner, J., Krzyżanowska, K., Kapiotis, S., Roden, M., & Wolzt, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2130 · Cited by 38
Second World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1821 · Cited by 37
Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
Nakajima, K. (2012) · International Journal of Hepatology · doi:10.1155/2012/950693 · Cited by 37
Leung, N. M., Naples, M., Uffelman, K. D., Szeto, L., Adeli, K., & Lewis, G. F. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.02.005 · Cited by 37
Interventions for managing antiretroviral therapy-associated lipoatrophy
Sutinen, J. (2005) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200502000-00005 · Cited by 37
Petalonia improves glucose homeostasis in streptozotocin-induced diabetic mice
Kang, S., Jin, Y.-J., Ko, H., Choi, S., Hwang, J., Whang, I., Kim, M.-H., Shin, H., Jeong, H.-B., & Kim, S. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.06.015 · Cited by 36
Gastaldelli, A., Casolaro, A., Ciociaro, D., Frascerra, S., Nannipieri, M., Buzzigoli, E., & Ferrannini, E. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90960.2008 · Cited by 37
Li, K., Li, L., Yang, M., Zong, H., Liu, H., & Yang, G. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0335 · Cited by 36
Tesaglitazar, a dual PPARα/γ agonist, ameliorates glucose and lipid intolerance in obese Zucker rats
Oakes, N. D., Thalén, P., Hultstrand, T., Jacinto, S. M., Camejo, G., Wallin, B., & Ljung, B. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00252.2005 · Cited by 36
Comparison of pioglitazone and metformin efficacy using homeostasis model assessment
Nagasaka, S., Aiso, Y., Yoshizawa, K., & Ishibashi, S. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01083.x · Cited by 36
Irons, B. K., Greene, R. S., Mazzolini, T. A., Edwards, K. L., & Sleeper, R. B. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.2.168 · Cited by 36
Wittrisch, S., Klöting, N., Mörl, K., Chakaroun, R., Blüher, M., & Beck‐Sickinger, A. G. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.009 · Cited by 34
DeFronzo, R. A., Mehta, R. J., & Schnure, J. J. (2013) · Hospital Practice · doi:10.3810/hp.2013.04.1062 · Cited by 35
Effects of prepartum 2,4-thiazolidinedione on metabolism and performance in transition dairy cows
Smith, K. L., Butler, W. R., & Overton, T. R. (2009) · Journal of Dairy Science · doi:10.3168/jds.2008-1508 · Cited by 35
Pioglitazone increases non-esterified fatty acid clearance in upper body obesity
Shadid, S., & Jensen, M. D. (2005) · Diabetologia · doi:10.1007/s00125-005-0051-0 · Cited by 35
Cade, W. T., Reeds, D. N., Mittendorfer, B., Patterson, B. W., Powderly, W. G., Klein, S., & Yarasheski, K. E. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00300.2006 · Cited by 34
Correlation between insulin resistance and intramyocellular lipid levels in rats
Kuhlmann, J., Neumann‐Haefelin, C., Belz, U., Kramer, W., Juretschke, H. P., & Herling, A. W. (2005) · Magnetic Resonance in Medicine · doi:10.1002/mrm.20501 · Cited by 33
Bahia, L., Kraemer‐Aguiar, L. G., Villela, N. R., Bottino, D. A., Godoy‐Matos, A. F., Geloneze, B., Tambascia, M. A., & Bouskela, E. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.09.003 · Cited by 33
Roche, M., Tarnus, E., Rondeau, P., & Bourdon, E. (2009) · Cell Biology and Toxicology · doi:10.1007/s10565-008-9118-2 · Cited by 33
Hu, C., Jia, W., Fang, Q., Zhang, R., Wang, C., Lu, J., & Xiang, K. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.02001.x · Cited by 33
Thiazolidinedione Response in Familial Lipodystrophy Patients with LMNA Mutations: A Case Series
Luedtke, A., Boschmann, M., Colpe, C., Engeli, S., Adams, F., Birkenfeld, A. L., Haufe, S., Rahn, G., Luft, F. C., Schmidt, H., et al. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0031-1301284 · Cited by 33
Rosiglitazone decreases 11β‐hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue
Mai, K., Andres, J., Bobbert, T., Maser‐Gluth, C., Möhlig, M., Bähr, V., Pfeiffer, A. F. H., Spranger, J., & Diederich, S. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02903.x · Cited by 33
Garretson, J. T., Teubner, B. J. W., Grove, K. L., Vazdarjanova, A. I., Ryu, V., & Bartness, T. J. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.2129-14.2015 · Cited by 32
Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats
Elshazly, S. M. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.12.017 · Cited by 33
Zhang, W., Wu, R., Zhang, F., Xu, Y.-Z., Liu, B., Yang, Y., Zhou, H., Wang, L., Wan, K., Xiao, X., et al. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12020 · Cited by 32
SEURAT-1 liver gold reference compounds: a mechanism-based review
Jennings, P., Schwarz, M., Landesmann, B., Maggioni, S., Γούμενου, Μ., Bower, D., Leonard, M. O., & Wiseman, J. S. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1410-8 · Cited by 35
Chou, H. S., Palmer, J. P., Jones, A. R., Waterhouse, B. R., Ferreira‐Cornwell, C., Krebs, J. D., & Goldstein, B. J. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00753.x · Cited by 33
Bernroider, E., Brehm, A., Krššák, M., Anderwald, C. H., Trajanoski, Z., Cline, G. W., Shulman, G. I., & Roden, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1756 · Cited by 32
Self-citationAdditive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes
Zander, M., Christiansen, A. L., Madsbad, S., & Holst, J. J. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1910 · Cited by 32
Bajpeyi, S., Pasarica, M., Conley, K. E., Newcomer, B. R., Jubrias, S. A., Gamboa, C., Murray, K. B., Sereda, O. R., Sparks, L. M., & Smith, S. R. (2016) · Metabolism · doi:10.1016/j.metabol.2016.11.016 · Cited by 31
Biondo, L. A., Teixeira, A. A. S., Ferreira, K. C. D. O. S., & Neto, J. C. R. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200122124116 · Cited by 31
Viljanen, A. P. M., Virtanen, K. A., Järvisalo, M. J., Hällsten, K., Parkkola, R. K., Rönnemaa, T., Lönnqvist, F., Iozzo, P., Ferrannini, E., & Nuutila, P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1073 · Cited by 32
Coort, S. L., Coumans, W. A., Bonen, A., Vusse, G. J., Glatz, J. F. C., & Luiken, J. J. F. P. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400426-jlr200 · Cited by 31
Chabowski, A., Żendzian‐Piotrowska, M., Nawrocki, A., & Górski, J. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2011.02380.x · Cited by 31
Thiazolinedione treatment in PCOS – an update
Glintborg, D., & Andersen, M. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.491572 · Cited by 30
Insulin sensitisation in the treatment of Type 2 diabetes
Tadayyon, M., & Smith, S. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.3.307 · Cited by 30
Cai, X., Hayashi, S., Fang, C., Hao, S., Wang, X., Nishiguchi, S., Tsutsui, H., & Sheng, J. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1332-3 · Cited by 29
Kursawe, R., Narayan, D., Cali, A. M. G., Shaw, M. M., Pierpont, B. M., Shulman, G. I., & Caprio, S. (2010) · Obesity · doi:10.1038/oby.2010.23 · Cited by 29
Self-citationRosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo‐Asian patients
Barnett, A. H., Grant, P. J., Hitman, G. A., Mather, H. M., Pawa, M., Robertson, L., & Trelfa, A. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00925.x · Cited by 29
Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to Practice
Bethel, M. A., & Sourij, H. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0229-7 · Cited by 28
Insulin Resistance Is Not Conserved in Myotubes Established from Women with PCOS
Eriksen, M. B., Pørneki, A. D., Skov, V., Burns, J. S., Beck‐Nielsen, H., Glintborg, D., & Gaster, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014469 · Cited by 29
Thiazolidinediones—Benefits on microvascular complications of type 2 diabetes
Viberti, G. C. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.04.001 · Cited by 28
Shishova, E. Y., Stoll, J. M., Ersoy, B. A., Shrestha, S., Scapa, E. F., Li, Y., Niepel, M. W., Su, Y., Jelicks, L. A., Stahl, G. L., et al. (2011) · Hepatology · doi:10.1002/hep.24393 · Cited by 28
Lipid Oxidation Assessed by Indirect Calorimetry Predicts Metabolic Syndrome and Type 2 Diabetes
Pujia, A., Mazza, E., Ferro, Y., Gazzaruso, C., Coppola, A., Doldo, P., Grembiale, R. D., Pujia, R., Romeo, S., & Montalcini, T. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00806 · Cited by 28
Poynten, A. M., Gan, S. K., Kriketos, A. D., Campbell, L. V., & Chisholm, D. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0943 · Cited by 28
Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands and Their Therapeutic Utility
Henke, B. R. (2004) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(04)42001-3 · Cited by 27
Sutinen, J. (2008) · PPAR Research · doi:10.1155/2009/373524 · Cited by 26
Hussein, O. S. M. E., Zidan, J., Jabal, K. A., Shams, I., Szvalb, S., Grozovski, M., Bersudsky, I., Karry, R., & Aviram, M. (2012) · International Journal of Hepatology · doi:10.1155/2012/265305 · Cited by 27
Impact of Glycemic Treatment Choices on Cardiovascular Complications in Type 2 Diabetes
Weiss, I. A., Valiquette, G., & Schwarcz, M. (2009) · Cardiology in Review · doi:10.1097/crd.0b013e3181a7b34c · Cited by 26
ROSIGLITAZONE: POTENTIAL BENEFICIAL IMPACT ON CARDIOVASCULAR DISEASE
Viberti, G. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10441.x · Cited by 27
Germano, D., Uteng, M., Pognan, F., Chibout, S., & Wolf, A. (2014) · Toxicology in Vitro · doi:10.1016/j.tiv.2014.05.009 · Cited by 26
Glesby, M. J., Albu, J., Chiu, Y., Ham, K., Engelson, E. S., He, Q. W., Muthukrishnan, V., Ginsberg, H. N., Donovan, D., Ernst, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061160 · Cited by 26
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Obese Children
Hecht, L., & Weiss, R. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0448-y · Cited by 26
Duez, H., Lamarche, B., Uffelman, K. D., Valéro, R., Szeto, L., Lemieux, S., Cohn, J. S., & Lewis, G. F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2110 · Cited by 26
Sajic, T., Hainard, A., Scherl, A., Wohlwend, A., Negro, F., Sanchez, J., & Szántó, I. (2013) · Scientific Reports · doi:10.1038/srep02350 · Cited by 25
Li, J., Xue, Y., Zhu, B., Pan, Y., Zhang, Y., Wang, C., & Li, Y. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4627842 · Cited by 23
Aydemir, D., Sarayloo, E., & Ulusu, N. N. (2019) · Journal of Medical Biochemistry · doi:10.2478/jomb-2019-0041 · Cited by 24
Insulin resistance due to lipid-induced signaling defects could be prevented by mahanine
Biswas, A., Bhattacharya, S., Dasgupta, S., Kundu, R., Roy, S. S., Pal, B. C., & Bhattacharya, S. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0257-4 · Cited by 25
Jucker, B. M., Schaeffer, T. R., Haimbach, R. E., Mayer, M. E., Ohlstein, D. H., Smith, S. A., Cobitz, A. R., & Sarkar, S. K. (2003) · Metabolism · doi:10.1053/meta.2003.50040 · Cited by 25
Effect of darglitazone on glucose clearance and lipid metabolism in obese cats
Hoenig, M. E., & Ferguson, D. C. (2003) · American Journal of Veterinary Research · doi:10.2460/ajvr.2003.64.1409 · Cited by 25
Glintborg, D., Hermann, A. P., Hagen, C., Jensen, L. T., Frystyk, J., Bennett, P., Flyvbjerg, A., & Andersen, M. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.12.082 · Cited by 25
Effective treatments for insulin resistance: trim the fat and douse the fire
Evans, J. L., YOUNGREN, J. F., & Goldfine, I. D. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.09.005 · Cited by 29
ELBATRAN, S., Abdel‐Salam, O. M. E., Nofal, S. M., & Baiuomy, A. R. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.08.008 · Cited by 25
Carmel, J., Tarnus, E., Cohn, J. S., Bourdon, E., Davignon, J., & Bernier, L. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22037 · Cited by 25
DAVIDSON, J., McMorn, S. O., WATERHOUSE, B., & Cobitz, A. R. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.011 · Cited by 25
Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model
Kim, H. J., Jung, T. W., Kang, E. S., Kim, D. J., Ahn, C. W., Lee, K. W., Lee, H. C., & Soo, B. (2007) · Metabolism · doi:10.1016/j.metabol.2006.12.017 · Cited by 24
Nonalcoholic Fatty Liver Disease
Sanyal, A. J. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.014 · Cited by 53
Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus
Singh, S. B., Bhat, J., & Wang, P. H. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0327-1 · Cited by 23
Aurantio‐obtusin improves obesity and insulin resistance induced by high‐fat diet in obese mice
Guo, C., Liao, W.-T., Qiu, R., Zhou, D., Ni, W., Yu, C., & Zeng, Y. (2020) · Phytotherapy Research · doi:10.1002/ptr.6805 · Cited by 23
Liu, Y., Wan, L.-S., Xiao, Z., Wang, J., Wang, Y., & Chen, J. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/349790 · Cited by 24
Lie, S., Hui, M., McMillen, I. C., Mühlhäusler, B. S., Posterino, G. S., Holman, S. L., Wang, K. C. W., Botting, K. J., & Morrison, J. L. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00431.2013 · Cited by 23
Gilliland, T., Dufour, S., Shulman, G. I., Petersen, K. F., & Emre, S. (2016) · Pediatric Transplantation · doi:10.1111/petr.12819 · Cited by 23
Self-citationDoležalová, R., Haluzík, M., Bošanská, L., Lacinová, Z., Štulc, T., & Haluzı́k, M. (2007) · Physiological Research · doi:10.33549/physiolres.931060 · Cited by 23
Gegick, C. G., & Altheimer, M. D. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003908 · Cited by 23
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 29
Kavak, S., Ayaz, L., Emre, M., İnal, T. C., Tamer, L., & Günay, İ. (2008) · Cell Biochemistry and Function · doi:10.1002/cbf.1469 · Cited by 22
Nuclear Receptors in Skeletal Homeostasis
Zuo, H., & Wan, Y. (2017) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2017.01.002 · Cited by 23
Approach to the management of diabetic patients with heart failure: Role of thiazolidinediones
Fonarow, G. C. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.033 · Cited by 22
Free Fatty Acid-Induced Insulin Resistance in the Obese Is Not Prevented by Rosiglitazone Treatment
Dhindsa, S., Tripathy, D., Sanalkumar, N., Ravishankar, S. T., Ghanim, H., Aljada, A., & Dandona, P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0223 · Cited by 22
TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse
Bernardi, S., Toffoli, B., Tisato, V., Bossi, F., Biffi, S., Lorenzon, A., Zauli, G., Secchiero, P., & Fabris, B. (2017) · Clinical Science · doi:10.1042/cs20171221 · Cited by 21
Hepatitis C and hepatic steatosis
Patel, J. H., Cobbold, J., Thomas, H. C., & Taylor-Robinson, S. D. (2010) · QJM · doi:10.1093/qjmed/hcp192 · Cited by 21
Evaluation of clinical activity and safety of Daflon 500 mg in type 2 diabetic female patients
Rizk, S. M., & Sabri, N. A. (2009) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2009.08.008 · Cited by 21
Metadata
- Authors
- Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F.
- Affiliations
- Yale University (US)
- Howard Hughes Medical Institute (US)
- Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2002-03-01
- Volume
- 51
- Issue
- 3
- Pages
- 797-802
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2995527
- OpenAlex
- W2100514340
- Cited by
- 647
- References
- 53
- Citations by year
- 2026: 12 · 2025: 6 · 2024: 11 · 2023: 15 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 20 · 2018: 12 · 2017: 15 · 2016: 15 · 2015: 22 · 2014: 20 · 2013: 22 · 2012: 16
- FWCI
- 24.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Yale University
- Deutsches Krebsforschungszentrum
- U.S. Public Health Service
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01DK049230, R01 DK-49230, K23DK002734, P30DK045735)
- National Center for Research Resources (M01RR000125, M01 RR-00125)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- rosiglitazone, thiazolidinediones, type 2 diabetes, insulin sensitivity, hepatic triglyceride content, extramyocellular lipids, plasma fatty acids, hyperinsulinemic-euglycemic clamp, microdialysis, lipid redistribution
- MeSH terms
- Rosiglitazone, Adipose Tissue, Blood Glucose, Body Composition, Calorimetry, Indirect, Diabetes Mellitus, Type 2, Fatty Acids, Glycerol, Glycated Hemoglobin, Humans, Hyperinsulinism, Insulin, Kinetics, Lipids, Lipolysis, Liver, Middle Aged, Magnetic Resonance Spectroscopy, Oxidation-Reduction, Thiazoles, Triglycerides, Glucose Clamp Technique, Microdialysis, Adipocytes, Muscle, Skeletal, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
